A personalized mRNA therapy passes a phase 3 melanoma trial for the first time

MercoPress MercoPress —


Despite the vaccine label used in much of the coverage, this is not a preventive measure but a treatmenthttps://en.mercopress.com/data/cache/noticias/111197/100x80/mod.jpeg" style="float: left; margin: 0 12px 6px 0; border: 1px solid #333;" width="100" />
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients.

It is the first positive result at that stage for an mRNA-based cancer treatment.

Read full article at MercoPress →